Neutrolis
Cambridge
About Neutrolis
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapy on the market that effectively targets and removes NETs. Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $23.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2021)
- Website: neutrolis.com
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/neutrolis-33963 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.